These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32113989)

  • 1. TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies.
    Wilkie MD; Anaam EA; Lau AS; Rubbi CP; Jones TM; Boyd MT; Vlatković N
    Cancer Lett; 2020 May; 478():107-121. PubMed ID: 32113989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
    Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
    Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
    Wilkie MD; Lau AS; Vlatkovic N; Jones TM; Boyd MT
    Oral Oncol; 2018 Aug; 83():1-10. PubMed ID: 30098763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells.
    Chang HW; Lee M; Lee YS; Kim SH; Lee JC; Park JJ; Nam HY; Kim MR; Han MW; Kim SW; Kim SY
    Cell Signal; 2021 Jan; 77():109820. PubMed ID: 33137455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxicity of the glycolytic inhibitor 2-deoxy-D-glucose in isogenic cell lines varying in their p53 status.
    Vibhuti A; Muralidhar K; Dwarakanath BS
    J Cancer Res Ther; 2013; 9(4):686-92. PubMed ID: 24518718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells.
    Fitzgerald AL; Osman AA; Xie TX; Patel A; Skinner H; Sandulache V; Myers JN
    Cell Death Dis; 2015 Mar; 6(3):e1678. PubMed ID: 25766317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
    Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
    PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
    Nylander K; Dabelsteen E; Hall PA
    J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
    Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-radiation enhances the cytotoxicity of docetaxel in head and neck squamous cell carcinoma cells.
    Furuse S; Adachi M; Ijichi K; Ohta S; Torigoe S; Nakazawa M; Miura S; Mitsudo K; Tohnai I
    Oncol Rep; 2010 May; 23(5):1339-43. PubMed ID: 20372849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck.
    Zhou S; Kachhap S; Sun W; Wu G; Chuang A; Poeta L; Grumbine L; Mithani SK; Chatterjee A; Koch W; Westra WH; Maitra A; Glazer C; Carducci M; Sidransky D; McFate T; Verma A; Califano JA
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7540-5. PubMed ID: 17456604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
    Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications.
    Wilkie M; Lau A; Vlatkovic N; Jones T; Boyd M
    Lancet; 2015 Feb; 385 Suppl 1():S101. PubMed ID: 26312831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
    Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
    Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
    Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.